Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Targeted drugs are increasingly being used for cancer management. They are designed to
block specific cancer cell processes, and are often better tolerated than conventional …

Chronic myeloid leukaemia in children and young people is a relatively rare form of
leukaemia that shows increased incidence with age and some evidence suggests that the …

Abstract The Therapeutic Intensification in De Novo Leukaemia (TIDEL)-II study enrolled
210 patients with chronic phase chronic myeloid leukemia (CML) in two equal, sequential …

Pleural effusion is a frequent side-effect of dasatinib, a second-generation tyrosine kinase
inhibitor used in the treatment of chronic myelogenous leukaemia. However, the underlying …

Chronic myeloid leukemia (CML), a myeloproliferative disorder caused by the over activity of
BCR-ABL1 (breakpoint cluster region-Abelson), has been successfully treated by Tyrosine …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm initiated by the presence
of the fusion gene BCR:: ABL1. The development of tyrosine kinase inhibitors (TKIs) highly …

Dasatinib, a second-generation tyrosine kinase inhibitor, is recommended as first-line
treatment for patients newly diagnosed with chronic myeloid leukemia (CML) and second …

Opinion statement The development of tyrosine kinase inhibitors (TKIs) dramatically
changed the treatment landscape for many different cancers including chronic myeloid …

Tyrosine kinase inhibitors (TKIs) targeting BCR/ABL such as imatinib, nilotinib, dasatinib,
bosutinib and ponatinib have revolutionised the management of patients with chronic …